These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17276681)

  • 21. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
    Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
    Marx IE; DiMauro EF; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Human J; Lee JH; Li X; Martin MW; White RD; Fremeau RT; Patel VF
    Bioorg Med Chem Lett; 2009 Jan; 19(1):31-5. PubMed ID: 19062274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
    Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
    Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
    J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
    Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D.
    Gamber GG; Meredith E; Zhu Q; Yan W; Rao C; Capparelli M; Burgis R; Enyedy I; Zhang JH; Soldermann N; Beattie K; Rozhitskaya O; Koch KA; Pagratis N; Hosagrahara V; Vega RB; McKinsey TA; Monovich L
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1447-51. PubMed ID: 21300545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.
    Hornberger KR; Chen X; Crew AP; Kleinberg A; Ma L; Mulvihill MJ; Wang J; Wilde VL; Albertella M; Bittner M; Cooke A; Kadhim S; Kahler J; Maresca P; May E; Meyn P; Romashko D; Tokar B; Turton R
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4511-6. PubMed ID: 23856049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
    Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SVM model for virtual screening of Lck inhibitors.
    Liew CY; Ma XH; Liu X; Yap CW
    J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.
    Meurer LC; Finke PE; Mills SG; Walsh TF; Toupence RB; Debenham JS; Goulet MT; Wang J; Tong X; Fong TM; Lao J; Schaeffer MT; Chen J; Shen CP; Sloan Stribling D; Shearman LP; Strack AM; Van der Ploeg LH
    Bioorg Med Chem Lett; 2005 Feb; 15(3):645-51. PubMed ID: 15664830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
    Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.